Abbott has earned U.S. Food and Drug Administration (FDA) clearance for its EnSite X EP system with EnSite OmniPolar Technology (OT), a cardiac mapping platform to help physicians better treat abnormal heart rhythms. It was designed with input from electrophysiologists around the globe, creating detailed 3D heart maps to help identify, then treat heart regions where arrhythmias originate.
 
“More patients than ever before are benefitting from ablation to treat abnormal heart rhythms, and Abbott’s new EnSite X System with EnSite OT, utilizing Advisor HD Grid catheter, embodies the latest innovation available to support the treatment of complex and challenging cardiac arrhythmias,” Amin Al-Ahmad, M.D., a clinical cardiac electrophysiologist with Texas Cardiac Arrhythmia at St. David’s Medical Center in Austin, Texas told the press. “To continue improving outcomes for our patients, we need a system with speed, stability and accuracy. Abbott has provided us with a system that not only supports safe and effective treatment, but enhances the accuracy of maps, allowing for a clearer understanding of what is going on in the heart and what areas need to be targeted with ablation to treat arrhythmias.”
 
Abbott’s EnSite OT uses the Advisor HD Grid Catheter to generate true electrograms (EGMs) regardless of the catheter’s orientation in the heart. The EnSite X EP system with EnSite OT can map one million points in the heart and enable more precision location of treatment areas.
 
AFib is the most common arrhythmia EnSite X EP with EnSite OT can treat. Untreated arrhythmias like AFib can lead to heart failure or stroke.
 
Physicians are increasingly using cardiac ablation to treat arrhythmias because the therapy treats the condition at the source by disrupting the area generating abnormal beats. Cardiac mapping is essential for ablation therapy due to highly precise, accurate, and detailed heart images enable determination of the best location to deploy therapy.
 
“As ablation therapy is increasingly used for patients battling cardiac arrhythmias, new, innovative and advanced cardiac mapping and imaging tools are essential to help physicians provide the best outcomes for their patients,” said Mike Pederson, senior vice president, electrophysiology Abbott. “We developed the EnSite X System with EnSite OT to enhance the utility of our unique Advisor HD Grid catheter and allow doctors to quickly and accurately create real-time, stable, three-dimensional models of the heart. These models provide a way to precisely identify areas that are causing problems, so physicians can better treat those abnormal heart rhythms, and preserve healthy tissue.”
 
The platform is upgradable via new software to ensure physicians have access to the latest technology without needing new systems. The system is also the first mapping system that lets clinicians choose between unipolar or bipolar measurement.